

Massimiliano Grassi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4620430/publications.pdf>

Version: 2024-02-01

15
papers

203
citations

1162889

8
h-index

1058333

14
g-index

15
all docs

15
docs citations

15
times ranked

378
citing authors

#	ARTICLE	IF	CITATIONS
1	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <i>Cancers</i> , 2020, 12, 1125.	1.7	43
2	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2625.	1.8	38
3	Nintedanib in non-small cell lung cancer: from preclinical to approval. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 164-172.	1.0	28
4	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , 2021, 10, 2645-2659.	1.3	23
5	Cabozantinib-related cardiotoxicity: a prospective analysis in a <i>real-world</i> cohort of metastatic renal cell carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1283-1289.	1.1	21
6	Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 658327.	1.3	12
7	Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature. <i>Molecular and Clinical Oncology</i> , 2019, 10, 58-66.	0.4	10
8	Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature. <i>Immunotherapy</i> , 2018, 10, 1123-1132.	1.0	9
9	Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour. <i>Anti-Cancer Drugs</i> , 2020, 31, 80-84.	0.7	7
10	A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 3412.	1.7	4
11	Multimodal treatment for local recurrent malignant gliomas: Resurgery and/or reirradiation followed by chemotherapy. <i>Molecular and Clinical Oncology</i> , 2019, 10, 49-57.	0.4	3
12	Cisplatin-related Atrial Fibrillation during PEB Chemotherapy for Testicular Seminoma: A Case Report. <i>Journal of Health & Medical Informatics</i> , 2016, 7, .	0.2	3
13	Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten. <i>Karger Kompass Pneumologie</i> , 2020, 8, 300-317.	0.0	1
14	Metastatic sarcoma: tailored strategies for a heterogeneous disease. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 179-184.	0.3	1
15	Quantitative investigation on perceived anxiety and pain during the cervical cancer screening path. <i>Minerva Psichiatrica: A Journal on Psychiatry, Psychology and Psychopharmacology</i> , 2018, 59, .	0.6	0